In Vitro Fertilization Clinical Trial
Official title:
The Influence of Dopamine Agonist Cabergoline on Oocyte Maturation in Women Undergoing Assisted Reproduction
The dopamine agonist cabergoline inhibits phosphorylation of the vascular endothelial growth factor receptor-2(VEGFR-2), which prevent vascular endothelial growth factor (VEGF) overexpression and reduce the severity of Ovarian hyperstimulation syndrome. However, VEGF plays an important role in the growth and maintenance of ovarian follicle and developing embryo by mediating angiogenesis.This study was designed to analyze whether the timing cabergoline administration on the day of human chorionic gonadotropin (hCG) injection or after oocytes retrieved affects the oocyte maturation and outcome of assisted reproduction treatment.
BACKGROUND:Ovarian hyperstimulation syndrome (OHSS) is the most serious complication of
ovulation induction. It results from increased vascular permeability caused by ovarian
hypersecretion of VEGF), which activates its receptor-2. The dopamine agonist cabergoline
inhibits phosphorylation of the receptor VEGFR-2, which prevent VEGF overexpression and
reduce the severity of OHSS. However, VEGF plays an important role in the growth and
maintenance of ovarian follicle and developing embryo by mediating angiogenesis. In human,
cabergoline averts OHSS, but a possible detrimental effect on oocyte maturation has not been
explored. This study was designed to analyze whether the timing cabergoline administration
on the day of hCG injection or after oocytes retrieved affects the oocyte maturation and
outcome of assisted reproduction treatment.
PURPOSE: To assess whether the timing cabergoline administration affects metaphase II
oocytes numbers, embryo quality, pregnancy outcome and the incidence of OHSS.
METHODS: A prospective randomized study was designed to evaluate the possible of cabergoline
affect on oocyte maturation. Women (n=120) under controlled ovarian hyperstimulation with
the risk of OHSS (Estradiol(E2)>4000 pg/ml, or >18 follicle, >11 mm development) randomized
into two groups. Group I (n=60) received 0.5 mg oral cabergoline per day for 8 days on the
day of hCG. Group II (n=60) received 0.5 mg oral cabergoline per day for 8 days on the day
after oocyte retrieval immediately.
ANTICIPATED RESULTS: No significant differences were seen in the number of metaphase II
oocytes, the embryo quality, the pregnancy rate and the incidence of OHSS.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00696878 -
Corifollitropin Alfa in Participants Undergoing Repeated Controlled Ovarian Stimulation (COS) Cycles Using a Multiple Dose Gonadatropin Releasing Hormone (GnRH) Antagonist Protocol (Study 38825)(P05714)
|
Phase 3 | |
| Recruiting |
NCT04122729 -
N680S Polymorphism of the FSHR Gene and Its Relationship With the Type of Gonadotropin Used in COS
|
||
| Not yet recruiting |
NCT02534857 -
A Study Comparing a Shorter Exposure of Oocyte to Spermatozoa Versus a Standard Incubation on the Live Birth Rate of In-vitro Fertilization Treatment
|
N/A | |
| Recruiting |
NCT01406600 -
Optimal rhCG(Ovidrel®) Dose in Poor Responder During IVF and ICSI Cycles
|
N/A | |
| Completed |
NCT01406028 -
Does Emotional Support Decrease In Vitro Fertilization Stress?
|
N/A | |
| Withdrawn |
NCT00541892 -
Sibling Oocyte Study of Medium for In Vitro Fertilization/Intracytoplasmic Sperm Injection (IVF/ICSI) With no Human Serum Albumine
|
Phase 2 | |
| Completed |
NCT00708383 -
in Vitro Fertilization (IVF) Media Protein and Live Birth Rates
|
N/A | |
| Completed |
NCT03627533 -
The Differences of Oocyte Maturation, Granulosa Cell Apoptosis Index Between Electroacupuncture And Sham Groups IVF
|
N/A | |
| Recruiting |
NCT04160611 -
What Amount of Stress is Enough for a Successful Conception?
|
Phase 3 | |
| Suspended |
NCT01600794 -
To Evaluate The Anrogens and Ovary Function in In Vitro Fertilization
|
N/A | |
| Completed |
NCT01507376 -
Comparing the Efficacy of Urinary and Recombinant Human Chorionic Gonadotropin (hCG) on Oocyte Maturity
|
Phase 3 | |
| Terminated |
NCT00866008 -
A Study of the Effects of a Novel Ovarian Stimulation Regimen on Embryo Aneuploidy Rates in In Vitro Fertilization (IVF)
|
Phase 4 | |
| Recruiting |
NCT04082650 -
Vitamin D and Pregnancy Outcome in PCOS Patients
|
N/A | |
| Recruiting |
NCT03758833 -
eSET or eDET Associated to PGT in IVF
|
N/A | |
| Not yet recruiting |
NCT04407871 -
Acupuncture and Chinese Herbal Medicine to Improve Live Birth Rate of in Vitro Fertilization (IVFAct)
|
N/A | |
| Recruiting |
NCT03345030 -
The Role of DNA Damage of Granulosa Cell on Oocyte Quality and in Vitro Fertilization Outcome
|
N/A | |
| Not yet recruiting |
NCT06367985 -
CAPA-IVM Culture With Low Oxygen Tension
|
N/A | |
| Not yet recruiting |
NCT03090438 -
IVF Outcomes After Varicocele Repair
|
N/A | |
| Terminated |
NCT01614067 -
Delayed Start to Ovarian Stimulation
|
Phase 4 | |
| Completed |
NCT01343992 -
Bed Rest or no Bed Rest?
|
N/A |